Ligands to peroxisome proliferator-activated receptors as therapeutic options for metabolic syndrome
Authors:
- Yanfang LiuYLYanfang Liu
- Anne Reifel MillerAMAnne Reifel Miller
- 1 June 2005
- journal article
- review article
- Published by Elsevier in Drug Discovery Today: Therapeutic Strategies
- Vol. 2 (2) , 165-169
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Prevalence and Trends of a Metabolic Syndrome Phenotype Among U.S. Adolescents, 1999–2000Diabetes Care, 2004
- Increasing Prevalence of the Metabolic Syndrome Among U.S. AdultsDiabetes Care, 2004
- Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the RoadMolecular Endocrinology, 2004
- PPARγ Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic MiceHypertension, 2004
- PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused ratsJournal of Molecular and Cellular Cardiology, 2004
- Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive PatientsDiabetes Care, 2003
- Bezafibrate Improves Hypertension and Insulin Sensitivity in HumansHypertension Research, 2003
- Thiazolidinediones in Type 2 Diabetes MellitusDrugs, 2003
- Peroxisome proliferator-activated receptors in macrophage biology: friend or foe?Current Opinion in Lipidology, 2001
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)Journal of Biological Chemistry, 1995